重点通报！任天堂Switch试玩新惊喜！欧服NSO会员免费畅玩《空洞骑士》

任天堂Switch试玩新惊喜！欧服NSO会员免费畅玩《空洞骑士》

任天堂宣布，面向欧洲地区Nintendo Switch Online会员的全新试玩同乐会活动将于2024年6月18日至24日举行。本次活动将免费提供人气银河恶魔城类游戏《空洞骑士》的完整版供玩家试玩。

《空洞骑士》由Team Cherry开发，2017年发售，在Metacritic上获得了90分的玩家评分和92分的媒体评分，被誉为“银河恶魔城类游戏的巅峰之作”。游戏讲述了一名无名骑士来到名为“空洞巢穴”的地下遗迹冒险的故事，玩家将探索错综复杂的地下世界，与各种奇形怪状的敌人战斗，揭开王国深处的秘密。

本次试玩活动为欧服NSO会员提供了体验《空洞骑士》的机会。如果在试玩期间对游戏感兴趣，玩家可以购买完整版游戏继续进行冒险。

除了《空洞骑士》之外，任天堂还经常在不同地区推出试玩同乐会活动，为玩家提供免费试玩各种游戏的机会。这些活动让玩家能够在购买前体验游戏，并发现更多潜在的佳作。

以下是一些试玩同乐会活动可以带来的益处：

• 帮助玩家发现新游戏：试玩同乐会活动可以让玩家接触到他们可能不会购买的全新游戏，并有可能发现新的喜爱。
• 降低购买风险：在购买游戏之前进行试玩可以帮助玩家了解游戏是否符合他们的口味，避免浪费金钱。
• 带来更多游戏选择：试玩同乐会活动可以丰富玩家的游戏选择，让他们在更广泛的游戏库中找到适合自己的游戏。

如果您是欧服NSO会员，请不要错过这次体验《空洞骑士》的机会！

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.